Skip to main content
. 2016 Dec 14;6(2):e1268310. doi: 10.1080/2162402X.2016.1268310

Figure 1.

Figure 1.

Tacromilus immune suppression can impact PyMT tumor latency in the C56BL/6 background. PyMT C56BL/6 mice were implanted at age (A) 43 d or (B) 77 d with a 13 mg biodegradable 90 d-releasable tacrolimus or placebo pellet in the interscapular region of the back, and tumor onset was recorded over time.